Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults

Experimental Gerontology

Volumn 73, Issue , 2016, Pages 86-94

  Hwang, Moon Hyon ^a,b   Yoo, Jeung Ki ^a   Luttrell, Meredith ^c   Kim, Han Kyul ^a   Meade, Thomas H ^d,e   English, Mark ^f   Talcott, Susanne ^g   Jaffe, Iris Z ^h   Christou, Demetra D ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b SolarLight Ltd   (South Korea)

^c UNIVERSITY OF OREGON   (United States)

^d SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^e TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^f Texas A and M University ^*  (United States)

^g TEXAS A AND M UNIVERSITY   (United States)

^h TUFTS MEDICAL CENTER   (United States)

Author keywords

Aging; Eplerenone; Mineralocorticoid receptor; Vascular function

Indexed keywords

ADIPONECTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPLERENONE; GLYCERYL TRINITRATE; ISOPROSTANE DERIVATIVE; MINERALOCORTICOID RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; VASCULOTROPIN; BIOLOGICAL MARKER; MINERALOCORTICOID ANTAGONIST; PLASMA PROTEIN; SPIRONOLACTONE;

ADULT; AGE DISTRIBUTION; AGED; ARTERY BLOOD FLOW; ARTICLE; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RESPONSE; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART FUNCTION; HEART RATE; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE COUNT; MALE; NEUTROPHIL; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SHEAR STRESS; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASODILATATION; VERY ELDERLY; AGING; ANALOGS AND DERIVATIVES; BLOOD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEMODYNAMICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULAR SMOOTH MUSCLE;

AGED; AGING; BIOMARKERS; BLOOD PROTEINS; BRACHIAL ARTERY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; VASODILATION;

EID: 84949564499     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2015.11.017     Document Type: Article

References (49)

1. Abiose A.K., Mansoor G.A., Barry M., Soucier R., Nair C.K., Hager D. Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. Am. J. Cardiol. 2004, 93:1564-1566.
2. Barrett Mueller K., Bender S.B., Hong K., Yang Y., Aronovitz M., Jaisser F., Hill M.A., Jaffe I.Z. Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension 2015, 66:988-997.
3. Bergmann A., Eulenberg C., Wellner M., Rolle S., Luft F., Kettritz R. Aldosterone abrogates nuclear factor kappaB-mediated tumor necrosis factor alpha production in human neutrophils via the mineralocorticoid receptor. Hypertension 2010, 55:370-379.
4. Caprio M., Newfell B.G., la Sala A., Baur W., Fabbri A., Rosano G., Mendelsohn M.E., Jaffe I.Z. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ. Res. 2008, 102:1359-1367.
5. Christou D.D., Gentile C.L., DeSouza C.A., Seals D.R., Gates P.E. Fatness is a better predictor of cardiovascular disease risk factor profile than aerobic fitness in healthy men. Circulation 2005, 111:1904-1914.
6. Christou D.D., Pierce G.L., Walker A.E., Hwang M.H., Yoo J.K., Luttrell M., Meade T.H., English M., Seals D.R. Vascular smooth muscle responsiveness to nitric oxide is reduced in healthy adults with increased adiposity. Am. J. Physiol. Heart Circ. Physiol. 2012, 303:H743-H750.
7. Colombo P.C., Ashton A.W., Celaj S., Talreja A., Banchs J.E., Dubois N.B., Marinaccio M., Malla S., Lachmann J., Ware J.A., Le Jemtel T.H. Biopsy coupled to quantitative immunofluorescence: a new method to study the human vascular endothelium. J. Appl. Physiol. 2002, 92:1331-1338.
8. Cook C.S., Berry L.M., Bible R.H., Hribar J.D., Hajdu E., Liu N.W. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab. Dispos. 2003, 31:1448-1455.
9. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., Deanfield J., Drexler H., Gerhard-Herman M., Herrington D., Vallance P., Vita J., Vogel R., International Brachial Artery Reactivity Task, F. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force.[erratum appears in J Am Coll Cardiol 2002 Mar 20;39(6):1082]. J. Am. Coll. Cardiol. 2002, 39:257-265.
10. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109:III27-III32.
11. Donato A.J., Black A.D., Jablonski K.L., Gano L.B., Seals D.R. Aging is associated with greater nuclear NF kappa B, reduced I kappa B alpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell 2008, 7:805-812.
12. Farquharson C.A., Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594-597.
13. Farquharson C.A., Struthers A.D. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin. Sci. (Lond.) 2002, 103:425-431.
14. Galmiche G., Pizard A., Gueret A., El Moghrabi S., Ouvrard-Pascaud A., Berger S., Challande P., Jaffe I.Z., Labat C., Lacolley P., Jaisser F. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension 2014, 63:520-526.
15. Gromotowicz A., Szemraj J., Stankiewicz A., Zakrzeska A., Mantur M., Jaroszewicz E., Rogowski F., Chabielska E. Study of the mechanisms of aldosterone prothrombotic effect in rats. J. Renin-Angiotensin-Aldosterone Syst. 2011, 12:430-439.
16. Huang P.L. Endothelial nitric oxide synthase and endothelial dysfunction. Curr. Hypertens. Rep. 2003, 5:473-480.
17. Hwang M.H., Yoo J.K., Luttrell M., Kim H.K., Meade T.H., English M., Nichols W.W., Christou D.D. Role of mineralocorticoid receptors in arterial stiffness in human aging. Exp. Gerontol. 2013, 48:701-704.
18. Hwang M.H., Yoo J.K., Luttrell M., Kim H.K., Meade T.H., English M., Segal M.S., Christou D.D. Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clin. Sci. (Lond.) 2013, 125:513-520.
19. Jaffe I.Z., Jaisser F. Endothelial cell mineralocorticoid receptors: turning cardiovascular risk factors into cardiovascular dysfunction. Hypertension 2014, 63:915-917.
20. Jaffe I.Z., Mendelsohn M.E. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ. Res. 2005, 96:643-650.
21. Keidar S., Kaplan M., Pavlotzky E., Coleman R., Hayek T., Hamoud S., Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004, 109:2213-2220.
22. Landmesser U., Drexler H. Endothelial function and hypertension. Curr. Opin. Cardiol. 2007, 22:316-320.
23. McCurley A., Jaffe I.Z. Mineralocorticoid receptors in vascular function and disease. Mol. Cell. Endocrinol. 2012, 350:256-265.
24. McCurley A., Pires P.W., Bender S.B., Aronovitz M., Zhao M.J., Metzger D., Chambon P., Hill M.A., Dorrance A.M., Mendelsohn M.E., Jaffe I.Z. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat. Med. 2012, 18:1429-1433.
25. Mihailidou A.S., Funder J.W. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 2005, 70:347-351.
26. Milne G.L., Sanchez S.C., Musiek E.S., Morrow J.D. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat. Protoc. 2007, 2:221-226.
27. Mitchell G.F., Parise H., Vita J.A., Larson M.G., Warner E., Keaney J.F., Keyes M.J., Levy D., Vasan R.S., Benjamin E.J. Local shear stress and brachial artery flow-mediated dilation: the Framingham heart study. Hypertension 2004, 44:134-139.
28. Moss M.E., Jaffe I.Z. Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis. Front. Endocrinol. 2015, 6:153.
29. Nagata D., Takahashi M., Sawai K., Tagami T., Usui T., Shimatsu A., Hirata Y., Naruse M. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006, 48:165-171.
30. Nietlispach F., Julius B., Schindler R., Bernheim A., Binkert C., Kiowski W., Brunner-La Rocca H.P. Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension 2007, 50:82-88.
31. Rajagopalan S., Duquaine D., King S., Pitt B., Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105:2212-2216.
32. Ras R.T., Streppel M.T., Draijer R., Zock P.L. Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. Int. J. Cardiol. 2012.
33. Ravis W.R., Reid S., Sica D.A., Tolbert D.S. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J. Clin. Pharmacol. 2005, 45:810-821.
34. Sartorio C.L., Fraccarollo D., Galuppo P., Leutke M., Ertl G., Stefanon I., Bauersachs J. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 2007, 50:919-925.
35. Schafer N., Lohmann C., Winnik S., van Tits L.J., Miranda M.X., Vergopoulos A., Ruschitzka F., Nussberger J., Berger S., Luscher T.F., Verrey F., Matter C.M. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur. Heart J. 2013, 34:3515-3524.
36. Schmidt B.M., Oehmer S., Delles C., Bratke R., Schneider M.P., Klingbeil A., Fleischmann E.H., Schmieder R.E. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 2003, 42:156-160.
37. Shenouda S.M., Widlansky M.E., Chen K., Xu G., Holbrook M., Tabit C.E., Hamburg N.M., Frame A.A., Caiano T.L., Kluge M.A., Duess M.A., Levit A., Kim B., Hartman M.L., Joseph L., Shirihai O.S., Vita J.A. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation 2011, 124:444-453.
38. Silver A., Beske S.D., Christou D.D., Donato A.J., Moreau K.L., Eskurza I., Gates P.E., Seals D.R. Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H Oxidase-p47phox expression and evidence of endothelial oxidative stress. Circulation 2007, 115.
39. Silver A.E., Christou D.D., Donato A.J., Beske S.D., Moreau K.L., Magerko K.A., Seals D.R. Protein expression in vascular endothelial cells obtained from human peripheral arteries and veins. J. Vasc. Res. 2010, 47:1-8.
40. Skott O., Uhrenholt T.R., Schjerning J., Hansen P.B., Rasmussen L.E., Jensen B.L. Rapid actions of aldosterone in vascular health and disease-friend or foe?. Pharmacol. Ther. 2006, 111:495-507.
41. Taye A., Morawietz H. Spironolactone inhibits NADPH oxidase-induced oxidative stress and enhances eNOS in human endothelial cells. Iran. J. Pharm. Res. 2011, 10:329-337.
42. Thai H.M., Do B.Q., Tran T.D., Gaballa M.A., Goldman S. Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J. Card. Fail. 2006, 12:240-245.
43. Thijssen D.H., Black M.A., Pyke K.E., Padilla J., Atkinson G., Harris R.A., Parker B., Widlansky M.E., Tschakovsky M.E., Green D.J. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H2-12.
44. Toda N., Nakanishi S., Tanabe S. Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br. J. Pharmacol. 2013, 168:519-533.
45. Vita J.A. Endothelial function. Circulation 2011, 124:e906-e912.
46. Walker A.E., Seibert S.M., Donato A.J., Pierce G.L., Seals D.R. Vascular endothelial function is related to white blood cell count and myeloperoxidase among healthy middle-aged and older adults. Hypertension 2010, 55:363-369.
47. White W.B., Carr A.A., Krause S., Jordan R., Roniker B., Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am. J. Cardiol. 2003, 92:38-42.
48. Williams G.H. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail. Rev. 2005, 10:7-13.
49. Yoo J.K., Hwang M.H., Luttrell M.J., Kim H.K., Meade T.H., English M., Segal M.S., Christou D.D. Higher levels of adiponectin in vascular endothelial cells are associated with greater brachial artery flow-mediated dilation in older adults. Exp. Gerontol. 2015, 63:1-7.